Sun Pharma приєднується до великого столу з придбанням Organon

THE GIST

Sun Pharmaceuticals will acquire New Jersey-based Organon & Co in an all-cash deal valued at $11.75 billion (plus debt), in the largest overseas acquisition made by an Indian pharmaceutical company.

Organon was spun off from Merck in 2021 and makes women’s health products including contraceptives, biosimilars for oncology and some older, off-patent drugs which are still making money.

WHAT HAPPENED

India’s biggest drugmaker catapulted into the top 25 global pharmaceutical companies with the purchase of Organon. The acquisition gives Sun Pharma an edge on pricing power, institutional investor attention, and access to larger distribution networks. Shareholders will receive $14 per share, a 24% premium to Organon's last close. The deal has board approval from both companies and is expected to close in early 2027.

This is the pivot Sun Pharma has been seeking. Organon will help reduce its over-dependence on generics and the U.S. market. Organon's portfolio adds meaningful exposure to developed markets outside the U.S., a strong women’s health franchise, and a biosimilars pipeline — all higher-margin, more defensible businesses than commodity generics.

The bulk of Organon’s business comes from older, off-patent drugs that still generate steady cash. These span cardiovascular, respiratory, dermatology, and non-opioid pain management. Notable names include Singulair (asthma), and Emgality (migraine, licensed from Eli Lilly). These brands are mature and slowly declining, but they throw off the cash that funds everything else. This cash cow that brings in $3.7 billion of revenue sits in slowly eroding older drugs, which is partly why Organon was carrying so much debt and trading cheap before this deal.

WHY IT MATTERS

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

For the broader Indian pharma sector, this signals a new era of ambition. Sun Pharma has made six acquisitions over 16 years — this one alone is larger than the others combined. It demonstrates that Indian drugmakers are now willing and capable of competing head-on with global pharma giants on deal size.

But it’s not without significant risk: debt, something Indian companies are squeamish about. Organon carries $8.6 billion in debt (a 4x net debt-to-EBITDA ratio) against just $574 million in cash.

This is a hugely leveraged business for Sun Pharma, which has historically been net cash positive. Post-deal, the combined net debt-to-EBITDA is projected at 2.3x. That's manageable, but it leaves little room for error. Integration costs, revenue disruption, or an economic downturn could stretch that ratio.